Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3011 + Toripalimab + Regorafenib in Liver Metastases from Colorectal Cancer
NCT06283303Phase 1Not yet recruiting
- Sponsor
- China Medical University
- Start
- Apr 2024
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
Phase 1, open-label, single-arm trial of MVR-T3011 in colorectal cancer (CRC), sponsored by China Medical University. Primary endpoint: Treatment Emergent Adverse Event. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
MVR-T3011
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06283303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06283303.